EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Long-term bleeding events post-percutaneous coronary intervention in patients with malignancy with and without anticoagulant therapy

Yasuhiro Otsuka, Masanobu Ishii, So Ikebe, Tatsuya Tokai, Taishi Nakamura, Kenichi Tsujita, Naoyuki Akashi, Hideo Fujita, Yasuhiro Nakano, Tetsuya Matoba, Takahide Kohro, Yusuke Oba und 12 weitere

Cardiovascular Intervention and Therapeutics · 2025-10 · 40 (4) · 796-806

DOI: 10.1007/s12928-025-01151-4 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cardiovascular Intervention and Therapeutics, online erschienen am 09.06.2025. Verfasst von Yasuhiro Otsuka und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: Percutaneous Coronary Intervention, Anticoagulants, Neoplasms, Warfarin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Labour Sciences Research Grant, Cross-ministerial Strategic Innovation Promotion Program on Integrated Health Care System, Kowa Company.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The prevalence of malignancies in patients undergoing percutaneous coronary intervention (PCI) is increasing with aging. Active malignancy is a significant contributor to high bleeding risk. For cancer patients requiring oral anticoagulant (OAC) therapy, the choice between direct oral anticoagulants (DOAC) and warfarin is critical. The aim of this study was to investigate long-term bleeding events in patients with malignancy undergoing PCI. The CLIDAS (Clinical Deep Data Accumulation System) multicenter database includes data from seven tertiary medical hospitals in Japan. This retrospective analysis included 6451 patients who underwent PCI between April 2013 and March 2019 and completed 3-year follow-up. The patients were divided into two groups; No malignancy (n = 5787) and Malignancy group (n = 664). Malignancy was defined by a history of cancer treatment. These groups were further subcategorized based on OAC therapy; (1) No malignancy without OAC (n = 5134), (2) No malignancy with DOAC (n = 261), (3) No malignancy with warfarin (n = 392), (4) Malignancy without OAC (n = 589), (5) Malignancy with DOAC (n = 38), and (6) Malignancy with warfarin (n = 37). The primary outcome was the incidence of bleeding events, defined according to the Global Use of Streptokinase and t-PA for Occluded Coronary Arteries classification of moderate and severe bleeding. The secondary outcomes were major adverse cardiac events (MACE) and net adverse clinical events (NACE). Multivariable Cox regression analysis showed that the malignancy with warfarin group had a significantly higher risk of bleeding events compared to the malignancy without OAC group (hazard ratio [HR], 3.64; 95% confidence interval [CI], 1.38–9.61, p value = 0.009). No significant differences were observed for MACE (HR, 1.39; 95% CI 0.59–3.25, p value = 0.454) or NACE (HR, 1.62; 95% CI, 0.80–3.29; p value = 0.184). Malignancy patients receiving warfarin were associated with a higher risk of bleeding events. DOACs may represent a preferable alternative to warfarin with regard to bleeding risk in patients with malignancy undergoing PCI. Graphical abstract Patients with malignancy receiving warfarin after PCI experienced a higher incidence of bleeding events. An analysis of 6,451 patients who underwent PCI revealed that only the group of patients with malignancy on warfarin therapy had a significantly higher incidence of bleeding events over the three-year postoperative period. PCI, percutaneous coronary intervention; OAC, oral anticoagulants; DOAC, direct oral anticoagulants; WF, warfarin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Percutaneous Coronary InterventionAnticoagulantsNeoplasmsWarfarinHemorrhageHumansMaleFemaleRetrospective StudiesAgedJapanMiddle AgedIncidenceRisk FactorsTime Factors

Stichwörter der Autor:innen

High bleeding riskMalignancyPCI

Substanzen

AnticoagulantsWarfarin

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan. mishii4@kumamoto-u.ac.jp.
  • Department of Medical Information Science, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo Chuo-Ku, Kumamoto, 860-8556, Japan. mishii4@kumamoto-u.ac.jp.
  • Department of Cardiovascular Medicine, Miyazaki Prefectural Nobeoka Hospital, Miyazaki, Japan.
  • Department of Medical Information Science, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo Chuo-Ku, Kumamoto, 860-8556, Japan.
  • Division of Cardiovascular Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.

Förderung

  • Health Labour Sciences Research Grant
  • Cross-ministerial Strategic Innovation Promotion Program on Integrated Health Care System
  • Kowa Company
  • Kumamoto University

Zitieren

APA

Otsuka, Y., Ishii, M., Ikebe, S., Tokai, T., Nakamura, T., Tsujita, K., Akashi, N., Fujita, H., Nakano, Y., Matoba, T., Kohro, T., Oba, Y., Kabutoya, T., Kario, K., Imai, Y., Kiyosue, A., Mizuno, Y., Nochioka, K., Nakayama, M., …, & CLIDAS research group (2025). Long-term bleeding events post-percutaneous coronary intervention in patients with malignancy with and without anticoagulant therapy. Cardiovascular Intervention and Therapeutics, 40(4), 796-806. https://doi.org/10.1007/s12928-025-01151-4

Vancouver

Otsuka Y, Ishii M, Ikebe S, Tokai T, Nakamura T, Tsujita K, et al. Long-term bleeding events post-percutaneous coronary intervention in patients with malignancy with and without anticoagulant therapy. Cardiovascular Intervention and Therapeutics. 2025;40(4):796-806. doi:10.1007/s12928-025-01151-4

BibTeX
@article{Otsuka2025,
  author = {Otsuka, Yasuhiro and Ishii, Masanobu and Ikebe, So and Tokai, Tatsuya and Nakamura, Taishi and Tsujita, Kenichi and Akashi, Naoyuki and Fujita, Hideo and Nakano, Yasuhiro and Matoba, Tetsuya and Kohro, Takahide and Oba, Yusuke and Kabutoya, Tomoyuki and Kario, Kazuomi and Imai, Yasushi and Kiyosue, Arihiro and Mizuno, Yoshiko and Nochioka, Kotaro and Nakayama, Masaharu and Iwai, Takamasa and Miyamoto, Yoshihiro and Sato, Hisahiko and Nagai, Ryozo and CLIDAS research group, CLIDAS research group},
  title = {Long-term bleeding events post-percutaneous coronary intervention in patients with malignancy with and without anticoagulant therapy},
  journal = {Cardiovascular Intervention and Therapeutics},
  year = {2025},
  volume = {40},
  number = {4},
  pages = {796--806},
  doi = {10.1007/s12928-025-01151-4}
}
Kostenlos starten →